Early Pseudomonas aeruginosa predicts poorer pulmonary function in preschool children with cystic fibrosis

Life expectancy of individuals born with cystic fibrosis (CF) has dramatically improved recently, largely because of closer monitoring, improved nutrition and more aggressive treatment of lung disease. Recent therapies targeting the primary CF defect are being trialled in infants and young children, potentially enabling a further step change in outcomes [1 –4], but this opportunity also brings a challenge. The age of development of significant lung disease is highly variable [5,6]. Targeting new treatments at infants with higher risk of developing disease could reduce the risk of potential medication side-effects, and save costs, in those for whom t here may be little benefit from very early treatment.

Source: Journal of Cystic Fibrosis - May 1, 2022 Category: Respiratory Medicine Authors: P. Aurora, Julie Anne Duncan, S. Lum, G. Davies, A. Wade, J. Stocks, L. Viviani, E. Raywood, C. Pao, G. Ruiz, A. Bush, London Cystic Fibrosis Collaboration (LCFC) Source Type: research